Adamis Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes products in the therapeutic areas of allergy and respiratory disease. It offers specialty pharmaceutical products for use in the emergency treatment of acute allergic reactions, and inhaler products for the treatment of bronchospasm, asthma, and chronic obstructive pulmonary disease. The company also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients. Adamis Pharmaceuticals merged with DMK Pharmaceuticals.